luminex corp (LMNX) Key Developments
Luminex Corporation Announces Launch of the NxTAG Respiratory Pathogen Panel
Apr 7 15
Luminex Corporation announced the launch of the NxTAG Respiratory Pathogen Panel (RUO). The NxTAG Respiratory Pathogen Panel is the only respiratory assay that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodate the higher throughput required to respond to seasonal changes in demand. The NxTAG Respiratory Pathogen Panel requires only minutes of hands-on time and no upstream reagent preparation. Extracted samples are added directly to pre-plated, lyophilized reagents. The tubes are then sealed and ready for closed tube amplification and subsequent detection using the Luminex MAGPIX instrument. The innovative tube strip design offers laboratories the flexibility to manage variable sample demand by processing a single sample or up to 96 samples per run without wasting consumables or reagents. The NxTAG Respiratory Pathogen Panel total turnaround time is approximately three hours for 96 samples (excluding extraction). The accompanying SYNCT™ Software provides a comprehensive approach to data analysis and reporting, and integrates the NxTAG Respiratory Pathogen Panel easily into any laboratory. Clinical trials for the NxTAG Respiratory Pathogen Panel are in progress in the U.S.
Luminex Corporation Endorses Mix&GoTM Activation Kit of Anteo Technologies Pty Ltd
Apr 6 15
Anteo Technologies Pty Ltd. announced that to provide shareholders with the link to a blog posted by Luminex Corporation that describes the performance and benefits of using Anteo Mix&GoTM (AMG) Activation Kit for Multiplex Microspheres on the Luminex xMAP platform. In line with Anteo Technologies' product pipeline development strategy, the company launched the AMG Activation Kit for Multiplex Microspheres in December 2014 to assist users of Luminex systems to more easily transfer their existing ELISA assays onto the Luminex platform. The AMG Activation Kit also allows users to troubleshoot proteins that are difficult to attach to Luminex microspheres using other methods. As previously reported, a number of Luminex partners are now engaged with Anteo and one is engaged in a study with clinical samples that is scheduled to conclude this quarter.
Luminex Corporation Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
Mar 31 15
Luminex Corporation announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay. Luminex plans to seek both FDA clearance and CE IVD marking in 2015. The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.
Assurex Health Selects Luminex Corporation's xTag Technology
Mar 12 15
Luminex Corporation announced that its xTAG Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight tests. Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, ADHD, and acute and chronic pain. This agreement incorporates the company's open-architecture xTAG Technology into the GeneSight testing process and enables large numbers of tests to be conducted and analyzed quickly, cost-effectively, and accurately.
Luminex Corporation Announces Amendments to the Articles of Incorporation
Mar 11 15
On March 4, 2015, the Board of Directors of Luminex Corporation adopted an amendment and restatement of the Company's amended and restated by-Laws to adopt a majority voting standard and director resignation process for uncontested director elections. The amendment and restatement affects Article III, Section 3.3 of the Company's Amended and Restated By-Laws. The Amended By-Laws became effective immediately upon their adoption by the Board. The Company's Amended and Restated Bylaws previously provided for a plurality voting standard in all director elections. The Amended By-Laws provide that in order to be elected in an uncontested election, a director nominee must receive a majority of the votes cast with respect to that nominee's election such that the number of votes cast for a nominee's election exceeds the number of votes withheld from that nominee. Abstentions and broker nonvotes are not counted as votes cast with respect to a nominee and will have no effect on the outcome of the election of directors. If an incumbent director nominee fails to receive for" votes representing a majority of the votes cast, the director is required to promptly tender his or her resignation to the Board, subject to acceptance by the Board. The Board's Nominating and Corporate Governance Committee would then be charged with making a recommendation to the Board as to the action to be taken with respect to the tendered resignation.